



Hepatitis C Drug Prior Authorization Removal

The Department of Healthcare and Family Services (HFS) will remove prior authorization requirements for preferred Hepatitis C drugs **effective July 1, 2023**.

Prescribing practitioners are required to get at least one hour of continuing medical education (CME) that is focused on diagnosis, appropriate management, and recommended follow-up of patients with Hepatitis C and approved or accredited by an organization such as: the Centers for Disease Control (CDC); the Accreditation Council for Continuing Medical Education (ACCME) or its state designee; a specialty society accredited to provide CME; an accredited medical school; or a university affiliated hospital.

HFS will be implementing a process for attestation of this required training through [IMPACT](#) via upload options. Prescribing practitioners must provide proof of training to HFS once the attestation process is established. HFS will supply additional information regarding the specifics of the attestation process when it becomes available. Any questions regarding this update may be directed to the Bureau of Professional and Ancillary Services at 877-782-5565.

Table 1. Effective July 1, 2023 Preferred Hepatitis C drugs no longer requiring PA.

LABEL NAME	THERAPEUTIC CLASS	PREVIOUS FORMULARY STATUS	NEW FORMULARY STATUS
MAVYRET	ANTIVIRALS: HEPATITIS C AGENTS	PREFERRED WITH PA	PREFERRED
SOFOSBUVIR/VELPATASVIR	ANTIVIRALS: HEPATITIS C AGENTS	PREFERRED WITH PA	PREFERRED

We look forward to working with you to ensure uninterrupted care for our members. Please contact CountyCarePharmacy@cookcountyhhs.org for additional information or assistance.